Biomica

Biomica is an emerging biopharmaceutical company that develops innovative microbiome-based therapies using a proprietary computational predictive biology platform (CPB) licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and develop new treatments based on these understandings. The company focuses on the development of treatments for antibiotic-resistant bacteria, immuno-oncology, and microbiome-associated gastrointestinal (GI) diseases.